Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026

Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026

Same author

CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link?

Blood advances·2026

Same author

Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.

Science signaling·2026

Same author

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.

Blood advances·2025

Same author

A CHIP off the old (MDS) block.

Haematologica·2025

Search research articles

Related Experiment Video

Updated: Oct 11, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Is the current consolidation regimen for AML evidence-based?

Selina M Luger¹

¹Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.

Best Practice & Research. Clinical Haematology

|December 6, 2021

Summary

For acute myeloid leukemia (AML) patients under 60, mid-dose cytarabine consolidation is effective, with 3-4 cycles and a 12-hour schedule showing optimal benefit and reduced toxicity. For older patients, optimal consolidation remains unknown but post-remission therapy may improve survival.

Keywords:

7+3 AML Acute myeloid leukemia Cytarabine

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Experiment Videos

Last Updated: Oct 11, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Standard of care for acute myeloid leukemia (AML) consolidation therapy is variable.
Optimal cytarabine dosing, cycle number, and schedule for AML consolidation are under investigation.
Patient age and induction regimen influence consolidation therapy choices.

Purpose of the Study:

To evaluate the efficacy and toxicity of different cytarabine consolidation regimens for AML.
To determine optimal cytarabine consolidation strategies based on patient age and other factors.
To assess the impact of post-remission therapy on survival in older AML patients.

Main Methods:

Review of current clinical trials and standard care practices for AML consolidation.
Comparative analysis of cytarabine dose, cycle number, and administration schedule.
Evaluation of post-remission therapy outcomes in AML patients over 60.

Main Results:

For AML patients under 60, mid-dose cytarabine is as effective as high-dose.
Three or four cycles of cytarabine consolidation are superior to one cycle.
A 12-hour schedule (days 1, 2, 3) offers similar benefits with less toxicity compared to a day 1, 3, 5 schedule.
Optimal cytarabine dose for patients over 60 is undetermined.
Post-remission therapy may enhance survival in select older AML patients, contingent on induction and MRD status.

Conclusions:

Cytarabine consolidation strategies can be optimized for younger AML patients.
Further research is needed to establish optimal consolidation for older AML patients.
Personalized post-remission therapy based on patient characteristics is crucial for improving AML outcomes.